59
Views
19
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials

&
Pages 2771-2777 | Published online: 09 Sep 2016

References

  • McInnesIBSchettGThe pathogenesis of rheumatoid arthritisN Engl J Med2011365232205221922150039
  • DaikhDISt ClairEWUpdated recommendations for the treatment of rheumatoid arthritis: another step on a long roadArthritis Care Res (Hoboken)201264564865122473919
  • SinghJAFurstDEBharatA2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)201264562563922473917
  • YaoZPainterSLFanslowWCHuman IL-17: a novel cytokine derived from T cellsJ Immunol199515512548354867499828
  • KiklyKLiuLNaSSedgwickJDThe IL-23/Th(17) axis: therapeutic targets for autoimmune inflammationCurr Opin Immunol200618667067517010592
  • MiossecPKornTKuchrooVKInterleukin-17 and type 17 helper T cellsN Engl J Med2009361988889819710487
  • ZiolkowskaMKocALuszczykiewiczGHigh levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanismJ Immunol200016452832283810679127
  • ChoMLYoonCHHwangSYEffector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: crosstalk between T cells and synovial fibroblastsArthritis Rheum200450377678415022319
  • KotakeSUdagawaNTakahashiNIL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclasto-genesisJ Clin Invest199910391345135210225978
  • RazaKFalcianiFCurnowSJEarly rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell originArthritis Res Ther200574R784R79515987480
  • ChabaudMDurandJMBuchsNHuman interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synoviumArthritis Rheum199942596397010323452
  • JoostenLARadstakeTRLubbertsEAssociation of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritisArthritis Rheum200348233934712571842
  • NistalaKMoncrieffeHNewtonKRVarsaniHHunterPWedderburnLRInterleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbersArthritis Rheum200858387588718311821
  • ChabaudMFossiezFTaupinJLMiossecPEnhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokinesJ Immunol199816114094149647250
  • GaffenSLRecent advances in the IL-17 cytokine familyCurr Opin Immunol201123561361921852080
  • PappKALeonardiCMenterABrodalumab, an anti-interleukin-17-receptor antibody for psoriasisN Engl J Med2012366131181118922455412
  • MiossecPKollsJKTargeting IL-17 and TH17 cells in chronic inflammationNat Rev Drug Discov2012111076377623023676
  • LubbertsEIL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?Cytokine2008412849118039580
  • GenoveseMCVan den BoschFRobersonSALY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept studyArthritis Rheum201062492993920131262
  • GenoveseMCDurezPRichardsHBEfficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyAnn Rheum Dis201372686386922730366
  • HueberWPatelDDDryjaTRheumatoid Arthritis Study Group, Uveitis Study GroupEffects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitisSci Transl Med201025252ra72
  • PatelDDLeeDMKolbingerFAntoniCEffect of IL-17A blockade with secukinumab in autoimmune diseasesAnn Rheum Dis201372Suppl 2ii116ii12323253932
  • MartinDAChurchillMFlores-SuarezLA phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritisArthritis Res Ther2013155R16424286136
  • JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
  • FelsonDTAndersonJJBoersMThe American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trialsArthritis Rheum19933667297408507213
  • PrevooMLvan ‘t HofMAKuperHHvan LeeuwenMAvan de PutteLBvan RielPLModified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis Rheum199538144487818570
  • HigginsJGreenSCochrane Handbook for Systematic Reviews of InterventionsChichester West Sussex, UKJohn Wiley & Sons Ltd2011
  • EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
  • KryczekIBruceATGudjonssonJEInduction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasisJ Immunol200818174733474118802076
  • HarperEGGuoCRizzoHTh17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesisJ Invest Dermatol200912992175218319295614
  • ZabaLCSuárez-FariñasMFuentes-DuculanJEffective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genesJ Allergy Clin Immunol20091245102210.e139519895991
  • LinAMRubinCJKhandpurRMast cells and neutrophils release IL-17 through extracellular trap formation in psoriasisJ Immunol2011187149050021606249
  • CaiYShenXDingCPivotal role of dermal IL-17-producing gammadelta T cells in skin inflammationImmunity201135459661021982596
  • LubbertsEJoostenLAOppersBIL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritisJ Immunol200116721004101311441109
  • NakaeSNambuASudoKIwakuraYSuppression of immune induction of collagen-induced arthritis in IL-17-deficient miceJ Immunol2003171116173617714634133
  • BushKAFarmerKMWalkerJSKirkhamBWReduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion proteinArthritis Rheum200246380280511920418
  • LubbertsEKoendersMIOppers-WalgreenBTreatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosionArthritis Rheum200450265065914872510
  • KoendersMILubbertsEOppers-WalgreenBBlocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1Am J Pathol2005167114114915972960
  • Abdollahi-RoodsazSJoostenLAHelsenMMShift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 productionArthritis Rheum200858123753376419035506
  • van LentPLGreversLCBlomABStimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritisArthritis Rheum200858123776378719035520
  • Abdollahi-RoodsazSJoostenLARoelofsMFInhibition of toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritisArthritis Rheum20075692957296717763416
  • RaychaudhuriSPRaychaudhuriSKGenoveseMCIL-17 receptor and its functional significance in psoriatic arthritisMol Cell Biochem20123591–241942921894442
  • JandusCBioleyGRivalsJPDudlerJSpeiserDRomeroPIncreased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritidesArthritis Rheum20085882307231718668556
  • NoordenbosTYeremenkoNGofitaIInterleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritisArthritis Rheum20126419910921968742
  • ShenHXiaLLuJXiaoWInfliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritisJ Investig Med2010587905908
  • KageyamaYKobayashiHKatoNInfliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritisMod Rheumatol200919665766219685204
  • KageyamaYKobayashiHKatoNShimazuMEtanercept reduces the serum levels of macrophage chemotactic protein-1 in patients with rheumatoid arthritisMod Rheumatol200919437237819458908
  • YueCYouXZhaoLThe effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patientsRheumatol Int201030121553155719847432
  • ZhangHLiHLiYIL-17 plays a central role in initiating experimental Candida albicans infection in mouse corneasEur J Immunol201343102671268223843112
  • SchmidtCSuicidal thoughts end Amgen’s blockbuster aspirations for psoriasis drugNat Biotechnol201533989489526348946
  • WilkowskaAPikułaMRynkiewiczAWdowczyk-SzulcJTrzonkowskiPLandowskiJIncreased plasma pro-inflammatory cytokine concentrations after myocardial infarction and the presence of depression during next 6-monthsPsychiatr Pol201549345546426276914
  • GenoveseMCGreenwaldMChoCSA phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitorsArthritis Rheumatol20146671693170424623718